Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Safety Problems Help AstraZeneca Win Suit Brought By Former Partner Verus

Executive Summary

AstraZeneca is in a strange position for a pharmaceutical company: It has benefited in court because of safety problems observed in one of its products

You may also be interested in...

Deals Of The Week: Merck/Portola, MedImmune/Catalyst, iZumi/Pierian ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at

Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug

Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.

From Verus to Meritage: A Biotech Prototype for Tough Economic Times

Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts